Fred H Mermelstein insider trades: Javelin Pharmaceuticals stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Fred reports to the SEC
Open-market buys and sales
2 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jun 26, 2008 | AMEX:JAV | ↑ Buy | 20,000 | $2.30 | $46K | Direct | Jun 27, 2008 (1d) |
| Nov 22, 2005 | JVPH.OB | ↑ Buy | 2,500 | $3.20 | $8K | Direct | Nov 23, 2005 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Fred H Mermelstein's insider trades
Fred H Mermelstein is Executive Director at Javelin Pharmaceuticals. Since Nov 22, 2005, Fred has reported 2 open-market purchases worth $54K and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (5 filings), shares returned to the company (1 filing), other transactions (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.